The Caring Ambassadors Program provides this website to help you and your loved ones understand your disease
and some of the healthcare option available to you.

Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your healthcare providers will be in the best possible situation to determine the best treatment approach for you.

Newly Diagnosed?

Caring Ambassadors has  released Lung Cancer Choices 3rd Edition, an amazing resource for those diagnosed with lung cancer.

Are you a Caregiver?

Caregiver Choicesa resource for all those who find themselves in the role of caregiver for someone who has been diagnosed with lung cancer.

Week Ending January 14, 2019

Could CRISPR reverse drug resistance in lung cancer?
“Using CRISPR/Cas9 gene editing combined with traditional chemotherapy, researchers “knocked out” (ie, removed) the nuclear factor erythroid 2-related factor (NRF2) gene to stop lung tumor growth and dramatically decrease tumor volume, according to researchers in a recently published article in Molecular Therapy Oncolytics.

Is Targeted Radiation Therapy Best for Your Early-Stage Lung Cancer?
“Your doctor says you have early-stage lung cancer. Although it’s always difficult to learn that you have cancer, outcomes are typically better when you catch and treat lung cancer in its early stages.”

Pyrotinib Shows Activity in HER2-Positive Non-Small Cell Lung Cancer
“Pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, showed activity against HER2-positive non-small cell lung cancer (NSCLC) in preclinical experiments and in a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02535507).1 The results were published online December 31, 2018, in Annals of Oncology.”

Treatment Breakthroughs Advance Care Across Heterogeneous NSCLC Population
“Single-agent immunotherapy, targeted therapies, and combinations of the 2 are demonstrating durable responses of up to 7 years in subsets of patients with advanced non–small cell lung cancer (NSCLC), giving physicians hope that the benefit can be extended to a greater proportion of patients, said Kwok-Kin Wong, MD, PhD.”

A Journey With Lung Cancer
“Two years ago, at the age of 55, Terri Ann DiJulio was diagnosed with lung cancer—for the second time.”

Presence of Preexisting Antibodies Linked With Clinical Benefit After Anti-PD-1 Therapy for NSCLC
“The presence of preexisting antibodies is associated with clinical benefit and the development of immune-related adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with anti-programmed cell death protein 1 (anti-PD-1) therapies nivolumab or pembrolizumab, according to a recent study.”

Targeted Therapies Extend Overall Survival in Patients with Stage 4 ALK-Positive Lung Cancer
“Half of patients diagnosed with stage 4, ALK-positive non-small cell lung cancer (NSCLC) from 2009 and 2017 were alive 6.8 years after diagnosis compared with just 2 percent of those diagnosed between 1995 and 2001 alive for five years, highlighting the importance of good targeted therapies, according to study findings published in the Journal of Thoracic Oncology.”

How radiologists can eliminate these 4 lung cancer screening barriers
“A new article published in Radiology explores the barriers patients face in undergoing lung cancer screening (LCS), and more importantly, what radiologists can do to encourage their participation.”

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy
“Despite previous findings, the response to immune checkpoint inhibitors does not differ between men and women, according to a systemic review and meta-analysis published in JAMA Oncology.”

Semaphorin linked to lung cancer treatment resistance
“Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR is known to be a particular risk factor for developing lung cancer and for the emergence of resistance to otherwise effective treatments, but the mechanism behind this has remained unclear.”

Broad-Panel NGS Benefits Metastatic NSCLC
“Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing (NGS) testing for patients with metastatic non–small cell lung cancer (NSCLC), according to an expert at Memorial Sloan Kettering (MSK) Cancer Center.”

Resistance to Therapy Clouds Treatment Successes in EGFR-, ALK-Positive NSCLC
“Although researchers and physicians have made advances in treatment options for patients with EGFR– and ALK-positive non–small cell lung cancer (NSCLC), a true understanding of the development of resistance to therapy is yet to emerge, according to D. Ross Camidge, MD, PhD.”

Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
“Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study from The University of Texas MD Anderson Cancer Center.”

Order Educational Materials

Free Brochures & Materials

Be Empowered by the Journey of a Lung Cancer Sur-THRIVE-er